Abstracts tagged "infliximab and pharmacokinetics"

Abstract Number: 615 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Primal Kaur¹, Vincent Chow², Nan Zhang³ and Eswar Krishnan⁴, ¹Amgen, Thousand Oaks, CA, ²Clinical Pharmacology, Amgen, Inc., Thousand Oaks, CA, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Biosimilars, Amgen, Inc, Thousand Oaks, CA
Background/Purpose: Methods: Results: Pharmacokinetics: A total of 49 subjects received ABP 710 and 50 subjects received infliximab. Following a single dose, the adjusted…
Abstract Number: 1509 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers
Dae-Hyun Yoo¹, Won Park², Seung-Cheol Shim³, Chang-Hee Suh⁴, Jihye Yun⁵ and Tina Pyo⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Chungnam National University Hospital, Daejeon, South Korea, ⁴Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁵CELLTRION, Inc, Incheon, South Korea
Background/Purpose CT-P13 has been approved as the first biosimilar to innovator infliximab sourced from European Union (EU‑INX) in Sep 2013. Even if it has been…
Abstract Number: 1501 • 2014 ACR/ARHP Annual Meeting
Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers
Chandrasekhar Udata¹, Donghua Yin², Chun-hua Cai³, Stephanie Salts⁴, Steven Y. Hua⁴, Muhammad I. Rehman⁵ and Xu Meng², ¹Clinical Pharmacology, Pfizer Inc., San Diego, CA, ²Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., San Diego, CA, ⁵Pfizer Inc., Cambridge, MA
Background/Purpose: PF-06438179, a proposed biosimilar to infliximab, was evaluated for immunogenicity in a phase 1 pharmacokinetic (PK) similarity study. Methods: In this double-blind trial (NCT01844804),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].